Potent suppression of proliferation of carcinoma cells by a novel non-nucleoside reverse transcriptase inhibitor

Autor:	William Schroeder, Osman V. Patel, Robert Smart, Alexander J. Fisch
Rok vydání:	2015
Předmět:	Cancer Research Cell signaling Telomerase business.industry Cancer medicine.disease Nucleoside Reverse Transcriptase Inhibitor chemistry.chemical_compound Oncology chemistry Cell culture Immunology Cancer research Carcinoma Medicine Trypan blue Viability assay business
Zdroj:	Journal of Clinical Oncology. 33:367-367
ISSN:	1527-7755 0732-183X
Popis:	367 Background: The treatment of choice for many patients with advanced carcinomas is surgery in combination with aggressive chemo- and radiotherapy. Unfortunately, even with the aggressive regime of therapy against carcinomas, there is neither guarantee of life-long remission nor of further spread to other organs including the urogenital system. However, recent advances have identified the reactivation of telomerase as a pivotal element in the development of cancer. Therefore, the objective of this study was to evaluate the efficacy of a novel anti-telomerase (GV6) developed at our Institution on MCF7 (ER+, PR+, HER2+) and MDA-MB 231 (ER-, PR-, HER2-) cell lines. Methods: Seeded flasks (T-75) were supplemented with 25μm GV6 (n=4-6) or solvent alone (control, n=3) for 14 (short-term) or 27 (long-term) days. Cell viability and replicative senescence were both assessed using the Trypan Blue (Gibco) and SA-β-Gal (Cell Signaling Tech) methods, respectively. Results: By day 27, MCF7 flasks had a greater (p
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::3e6ad609218ff742a10fc34102d2a2f1 https://doi.org/10.1200/jco.2015.33.7_suppl.367 Zobrazit plný text záznamu